Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487053 | 0.83 | FYN (0.47) | ALDH1A1L3MBTL1CYP3A4CYP2D6 | |
| SCHEMBL4301998 | 0.82 | SCN9A (0.47) | SCN9ASCN10ACYP2C9ALDH1A1L3MBTL1 | |
| SCHEMBL4307227 | 0.80 | KMO (0.47) | SCN9ASCN10AALDH1A1CYP3A4GPBAR1 | |
| SCHEMBL27473965 | 0.77 | MKNK1 (0.46) | ALDH1A1L3MBTL1CYP3A4GPBAR1 | |
| SCHEMBL23199045 | 0.74 | NTRK1 (0.52) | ALDH1A1 | |
| SCHEMBL15391364 | 0.74 | SCN9A (0.50) | SCN9ASCN10ACYP2C9ALDH1A1L3MBTL1 | |
| SCHEMBL21490297 | 0.74 | SCN9A (0.50) | SCN9ASCN10ACYP2C9ALDH1A1L3MBTL1 | |
| SCHEMBL4302004 | 0.73 | SCN9A (0.43) | SCN9ASCN10ACYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL2560966 | 0.72 | HSD11B1 (0.41) | SCN9ACYP2C9ALDH1A1L3MBTL1CYP2D6 | |
| SCHEMBL20767113 | 0.72 | MKNK1 (0.51) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | claimed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | SCN9A 117/4885SCN10A 90/4885CYP2C9 4320/4885 |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | SCN9A 117/4885SCN10A 90/4885CYP2C9 4320/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | SCN9A 117/4885SCN10A 90/4885CYP2C9 4320/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | SCN9A 2437/4885SCN10A 1733/4885CYP2C9 216/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | SCN9A 117/4885SCN10A 90/4885CYP2C9 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.